Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure

@inproceedings{Kawamura2016RebiopsyFP,
  title={Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure},
  author={Takahisa Kawamura and Hirotsugu Kenmotsu and Tetsuhiko Taira and Shota Omori and Kazuhisa Nakashima and Kazushige Wakuda and Akira Ono and Tateaki Naito and Haruyasu Murakami and Keita Mori and Takashi Nakajima and Yasuhisa Ohde and Masahiro Endo and Toshiaki Takahashi},
  booktitle={Cancer science},
  year={2016}
}
Although third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) can overcome T790M-mediated resistance in non-small-cell lung cancer (NSCLC), rebiopsy to confirm T790M status is occasionally difficult. We aimed to investigate the current tendency and the limitations of rebiopsy in clinical practice. This study included 139 consecutive NSCLC patients with EGFR mutations, who had experienced progressive disease (PD) after EGFR-TKI treatment. We retrospectively… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686)

KS Thress, R Brant, TH Carr
Clin Cancer Res • 2016

Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.

The New England journal of medicine • 2015

Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2015

growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer

DA Cross, SE Ashton, S Ghiorghiu
Cancer • 2015

technologies to support the clinical development of AZD9291

D Jackman, W Pao, GJ Riely
Lung Cancer • 2015

AZD 9291 , an irreversible EGFR TKI , overcomes T 790 M - mediated resistance to EGFR inhibitors in lung can

DA Cross, SE Ashton, S Ghiorghiu
Cancer Discov • 2014

Similar Papers

Loading similar papers…